Skip to main content
MedPathMedPath Home
Clinical Trials/jRCT1030260018
jRCT1030260018
Recruiting
Not Applicable

An observational study on the safety and therapeutic effects of oral administration of Quercefit in subjects with aging symptoms

Not provided0 sites10 target enrollmentStarted: TBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsAge-related decline in physical function and aging-associated symptoms

Overview

Phase
Not Applicable
Status
Recruiting
Enrollment
10
OverviewStudy DesignEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
20age old over to No limit (—)
Sex
All

Inclusion Criteria

  • •1.Male or female aged 20 years or older at the time of informed consent.
  • •2.Individuals who complain of aging symptoms, such as physical decline or chronic fatigue.
  • •3.Individuals who fully understand the study and provide written voluntary informed consent.

Exclusion Criteria

  • •Patients who were unable to continue due to hypersensitivity or allergic reactions to organic germanium.
  • •Patients who are taking other drugs concomitantly, or patients who have previously participated in clinical trials and have not yet been on the last dose of the test drug for more than one month.
  • •Patients who are otherwise deemed inappropriate by the principal investigator or co-investigator.

Investigators

Sponsor
Not provided

Similar Trials

Recruiting
Phase 1/2
A study to investigate the safety and clinical activity of belantamab for the treatment of multiple myeloma when used as monotherapy and in combination treatments.
2022-501941-63-00Glaxosmithkline Research & Development Limited3
Not yet recruiting
Phase 1
A clinical study to investigate the safety, tolerability and pharmacokinetic profile of single ascending concentrations of OPT101 in peritoneal dialysis patients.
2025-522966-61-00OPTERION Health AG12
Recruiting
Not Applicable
A Clinical Study of Islatravir/MK-8507 (MK-8591B) in Healthy Japanese ParticipantsHIV infection
jRCT203125065524
Recruiting
Phase 1/2
Clinical study to evaluate the safety and tolerability of SPVN06 (novel gene therapy) in a subset of patients with rod cone dystrophy (RCD).
2022-501250-12-01Sparingvision17
Recruiting
Phase 1
Clinical study to test the safety, tolerance and preliminary efficacy of oral ITF3756 administered alone or in combination with an anti-protein 4 agent associated with cytotoxic T lymphocytes in patients with advanced solid tumors.
2022-501089-22-00Italfarmaco S.p.A.60